TGFBI secreted by mesenchymal stem cells ameliorates osteoarthritis and is detected in extracellular vesicles.
Biomaterials. 2020 Jan;226:119544. doi: 10.1016/j.biomaterials.2019.119544. Epub 2019 Oct 11.
Ruiz M1, Toupet K1, Maumus M1, Rozier P1, Jorgensen C2, Noël D3.
- IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.
- IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France; Hôpital Lapeyronie, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Montpellier, France.
- IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France; Hôpital Lapeyronie, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Montpellier, France. Electronic address: [email protected]
Mesenchymal stem/stromal cells (MSCs) are of interest in the context of osteoarthritis (OA) therapy. We previously demonstrated that TGFβ-induced gene product-h3 (TGFBI/BIGH3) is downregulated in human MSCs (hMSCs) from patients with OA, suggesting a possible link with their impaired regenerative potential. In this study, we investigated TGFBI contribution to MSC-based therapy in OA models. First, we showed that co-culture with murine MSCs (mMSCs) partly restored the expression of anabolic markers and decreased expression of catabolic markers in OA-like chondrocytes only upon priming by TGFβ3. Moreover, TGFβ3-primed hMSCs not only modulated the expression of anabolic and catabolic markers, but also decreased inflammatory factors. Then, we found that upon TGFBI silencing, mMSCs partly lost their inductive effect on chondrocyte anabolic markers. Injection of hMSCs in which TGFBI was silenced did not protect mice from OA development. Finally, we showed that MSC chondroprotection was due to the presence of TGFBI mRNA and protein in extracellular vesicles. Our findings suggest that TGFBI is a chondroprotective factor released by MSCs and an anabolic regulator of cartilage homeostasis.
Copyright © 2019 Elsevier Ltd. All rights reserved.